<DOC>
	<DOCNO>NCT02749435</DOCNO>
	<brief_summary>A real-world , point-of-care , randomize , parallel group , open , 6-month clinical study evaluate provision digital disease management tool improve glycaemic control participant type 2 diabetes mellitus ( T2DM ) , measure change baseline End Study ( Month 6 ) glycosylated haemoglobin ( HbA1c ) level . Clinical assessment study conduct part normal , standard care . The main objective study evaluate effect add tool participant ' current standard care T2DM glycaemic control , variable importance T2DM ( eg , weight , blood pressure , lipid level ) , participant-reported outcome ( PROs ) , satisfaction treatment adherence antihyperglycaemic treatment</brief_summary>
	<brief_title>A Study Evaluate Effect Digital Disease Management Tool Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The purpose study evaluate provision digital disease management tool addition standard care T2DM , improve glycaemic control . This open design study , patient aware guidance receiving via provided support tool . Study duration 6 month choose , reasonable amount time evaluate tool . Glycaemic control consider goal T2DM disease management plan . In T2DM , long-term goal may achieve participant fail adhere management plan initial period compliance . The study compare group receive digital disease management tool add standard care T2DM concurrent control group receive standard care . Standard Care cohort : Participants standard care access digital disease management tool . Clinical assessment study conduct part normal , standard care . Participants Standard Care + digital disease management cohort take standard T2DM management plan HCP ( Health Care Provider ) train use digital disease management tool . All participant complete PRO assessment . This study also aim help health care practitioner manage care provider make evidence-based decision improve patient self-management diabetes . Participants diagnose T2DM one non-insulin antihyperglycaemic medication offer participation study point care . Participants Standard Care cohort take T2DM management plan HCP per standard care . It anticipate use patient tool associate increase risk participate patient . The study perform accordance ethical principle consistent International Conference Harmonisation ( ICH ) /Good Clinical Practice ( GCP ) , applicable regulatory requirement , AZ policy bioethics .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : For inclusion study participant must fulfill follow criterion : Provision write informed consent prior studyspecific procedure . Female male age ≥18 year time consent . Diagnosed T2DM . Treatment one noninsulin antihyperglycaemic medication ( ) least 6 month prior enrolment Own/have access smart phone internet access access internet via tablet personal computer least day . At HCP 's discretion , patient may without access smart phone service , data connection , internet access period time ≤2 consecutive week HbA1c level ≥8.0 % ≤11.0 % within last 6 month . If 1 value available 6month time period , value must within range Body mass index ( BMI ) ≥25 ≤55 kg/m2 within last 3 month Ability communicate English Judged HCP suitable hearing , vision , manual dexterity , ability understand instruction , ability use understand smart phone internet application Negative pregnancy test ( urine serum ) female patient childbearing potential Exclusion criterion : Participants enter study follow exclusion criterion fulfil : Pregnancy Insulin use baseline Current use smart phone web portalbased tool help management T2DM History type I diabetes ketoacidosis Currently take weight loss medication Involvement planning and/or conduct study ( applies AZ staff and/or staff affiliate study site ) Previous enrolment present study Participation clinical study investigational product disease state management program last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Digital disease management tool</keyword>
	<keyword>Type 2 diabetes mellitus/ T2DM</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Standard care</keyword>
	<keyword>PRO questionnaire</keyword>
	<keyword>Smart phone/ personal computer internet access</keyword>
</DOC>